(Reuters) – COVID-19 vaccines from U.S. drugmaker Johnson & Johnson and China’s Sinopharm as well as Russia’s Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.
Vaccines from Moderna, AstraZeneca and Pfizer and partner BioNTech retained activity against Omicron with some decreases, the study, conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others, showed.
(Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri)
